GSK, Jefferies
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...
Walmsley told journalists the company has "some pressure short-term on vaccines", but said that its "medium and long-term prospects" for both Arexvy and Shingrix are strong. GSK beat analyst ...
12d
GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...
For the remainder of the year, management expects a fall in Vaccine sales due to lower sales of Arexvy and Shingrix. GSK now expects sales to decline by a low-single digit percentage at CER ...
The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease by a low-single digit percentage. GSK's (GSK) shares are falling 4% in premarket trading ...
GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback